![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: PROSER1 |
Gene summary for PROSER1 |
![]() |
Gene information | Species | Human | Gene symbol | PROSER1 | Gene ID | 80209 |
Gene name | proline and serine rich 1 | |
Gene Alias | C13orf23 | |
Cytomap | 13q13.3 | |
Gene Type | protein-coding | GO ID | NA | UniProtAcc | Q86XN7 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
80209 | PROSER1 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 3.46e-03 | 3.52e-01 | 0.294 |
80209 | PROSER1 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 6.68e-05 | 5.14e-01 | 0.281 |
80209 | PROSER1 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 7.20e-17 | 7.33e-01 | 0.3859 |
80209 | PROSER1 | A015-C-203 | Human | Colorectum | FAP | 9.92e-03 | -5.92e-02 | -0.1294 |
80209 | PROSER1 | A002-C-205 | Human | Colorectum | FAP | 2.23e-04 | -1.38e-01 | -0.1236 |
80209 | PROSER1 | A015-C-104 | Human | Colorectum | FAP | 2.07e-07 | -1.66e-01 | -0.1899 |
80209 | PROSER1 | A002-C-016 | Human | Colorectum | FAP | 2.41e-03 | -1.06e-01 | 0.0521 |
80209 | PROSER1 | A002-C-116 | Human | Colorectum | FAP | 2.97e-07 | -1.12e-01 | -0.0452 |
80209 | PROSER1 | CRC-1-8810 | Human | Colorectum | CRC | 8.69e-04 | 3.60e-01 | 0.6257 |
Page: 1 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PROSER1 | SNV | Missense_Mutation | novel | c.2140N>G | p.Ser714Ala | p.S714A | Q86XN7 | protein_coding | tolerated(0.96) | benign(0) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PROSER1 | SNV | Missense_Mutation | novel | c.2068A>T | p.Ile690Phe | p.I690F | Q86XN7 | protein_coding | deleterious_low_confidence(0.02) | benign(0.424) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
PROSER1 | SNV | Missense_Mutation | c.1846N>T | p.Pro616Ser | p.P616S | Q86XN7 | protein_coding | tolerated(0.14) | possibly_damaging(0.836) | TCGA-AR-A1AL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | anastrozole | SD | |
PROSER1 | SNV | Missense_Mutation | c.2164N>A | p.Pro722Thr | p.P722T | Q86XN7 | protein_coding | deleterious_low_confidence(0.01) | benign(0.007) | TCGA-BH-A0AW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD | |
PROSER1 | SNV | Missense_Mutation | rs777591348 | c.1748N>T | p.Arg583Leu | p.R583L | Q86XN7 | protein_coding | deleterious_low_confidence(0.04) | benign(0) | TCGA-BH-A0AY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | SD | |
PROSER1 | SNV | Missense_Mutation | c.219N>G | p.Ile73Met | p.I73M | Q86XN7 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-EW-A1IZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | SD | |
PROSER1 | SNV | Missense_Mutation | novel | c.310G>A | p.Glu104Lys | p.E104K | Q86XN7 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-LL-A5YL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
PROSER1 | SNV | Missense_Mutation | novel | c.1567N>T | p.Ala523Ser | p.A523S | Q86XN7 | protein_coding | tolerated_low_confidence(0.05) | possibly_damaging(0.57) | TCGA-EA-A3HS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
PROSER1 | SNV | Missense_Mutation | c.2255C>G | p.Ser752Cys | p.S752C | Q86XN7 | protein_coding | tolerated(0.07) | benign(0.346) | TCGA-Q1-A73P-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
PROSER1 | SNV | Missense_Mutation | novel | c.1690N>A | p.Ala564Thr | p.A564T | Q86XN7 | protein_coding | tolerated_low_confidence(0.43) | benign(0.036) | TCGA-VS-A94Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |